靶向使用CT冠状动脉造影在急性胸痛中的应用
该多中心RCT纳入14家英国医院3170例急诊疑似急性冠脉综合征、已排除心梗且高敏肌钙蛋白提示中危(>5 ng/L)的患者,随机分为门诊CT冠脉造影指导组或标准治疗组。90天内CT组92.1%完成检查,标准组2.2%。中位随访3.0年,主要终点(心梗或心源性死亡)发生率CT组7.1%、标准组7.3%,校正HR 0.95(95%CI 0.73-1.23,P=0.71)。CT冠脉造影相关不良事件0.4%。
要点
- 适用人群:急诊疑似急性冠脉综合征、已排除心梗、高敏肌钙蛋白I或T>5 ng/L提示中危的患者。
- 干预:门诊CT冠脉造影指导治疗;对照:标准治疗;随机1:1,14家医院,3170例。
- 主要终点(心梗或心源性死亡)CT组7.1% vs 标准组7.3%,校正HR 0.95(95%CI 0.73-1.23,P=0.71)。
- CT冠脉造影相关不良事件发生率0.4%(7例)。
- 中位随访3.0年,常规CT冠脉造影指导管理未优于标准治疗。
适用人群与场景
- 急诊就诊的疑似急性冠脉综合征患者,已排除心肌梗死且高敏肌钙蛋白I或T最高浓度>5 ng/L提示中危心血管事件风险。
- 来自英国14家医院的多中心随机对照试验人群,中位年龄61岁,女性30.2%。
诊断标准与关键阈值
- 心肌梗死已排除:原文未提及具体排除标准细节。
- 高敏肌钙蛋白I或T最高浓度>5 ng/L定义为中危心血管事件风险。
处置流程与药物剂量
- 随机1:1分配至门诊CT冠脉造影指导治疗或标准治疗。
- CT冠脉造影组90天内92.1%(1462例)完成检查;标准治疗组2.2%(35例)完成检查。
- 原文未提及具体药物剂量、给药途径或频次。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 多中心随机对照试验,14家英国医院,3170例患者随机(CT组1587例,标准组1583例)。
- 主要终点为心肌梗死或心源性死亡的复合终点;中位随访3.0年,CT组112例(7.1%),标准组116例(7.3%)。
- 校正HR 0.95(95%CI 0.73-1.23,P=0.71)。
- CT冠脉造影相关不良事件7例(0.4%)。
- 标准组主要终点事件数超过预设最低97例后进行分析。
证据类型、等级与局限
- 随机对照试验(RCT),多中心(14家医院)。
- 局限:开放标签设计(原文未明确提及盲法),随访期间标准组2.2%交叉接受CT冠脉造影。
对床旁实践的改变
- 对于急诊疑似急性冠脉综合征、已排除心梗且高敏肌钙蛋白>5 ng/L的中危患者,常规门诊CT冠脉造影指导管理不改变后续心梗或心源性死亡风险,不应作为常规策略。
- CT冠脉造影相关不良事件发生率0.4%,需权衡检查风险。
- 原文未提及适用与不适用人群的进一步区分。
指南或共识出处
- TARGET-CTCA试验(ClinicalTrials.gov NCT03952351),由英国心脏基金会资助,发表于N Engl J Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Many patients with suspected acute coronary syndrome in whom myocardial infarction has been ruled out in the emergency department remain at risk for cardiovascular events. Whether further investigation reduces this risk is unknown.
METHODS: In a multicenter, randomized, controlled trial, patients who presented to an emergency department in 14 hospitals across the United Kingdom were enrolled if myocardial infarction had been ruled out and high-sensitivity cardiac troponin testing indicated an intermediate risk of a cardiovascular event (maximum high-sensitivity cardiac troponin I or T concentration, >5 ng per liter). Participants were randomly assigned in a 1:1 ratio to receive either outpatient computed tomographic (CT) coronary angiography-guided care or standard care. The primary outcome was a composite of myocardial infarction or death from a cardiac cause.
RESULTS: From September 18, 2019, to May 11, 2023, a total of 3170 participants (median age, 61 years; female sex, 30.2%) were assigned to undergo CT coronary angiography (1587 participants) or receive standard care (1583 participants). At 90 days after randomization, CT coronary angiography had been performed in 1462 participants (92.1%) in the CT coronary angiography group and in 35 participants (2.2%) in the standard-care group. Overall, 7 participants (0.4%) had a CT coronary angiography-related adverse event. After a median of 3.0 years, at which point the number of primary-outcome events in the standard-care group exceeded the prespecified minimum of 97, a primary-outcome event had occurred in 112 participants (7.1%) in the CT coronary angiography group and in 116 (7.3%) in the standard-care group (adjusted hazard ratio, 0.95; 95% confidence interval, 0.73 to 1.23; P = 0.71).
CONCLUSIONS: In patients with suspected acute coronary syndrome in whom myocardial infarction had been ruled out, routine CT coronary angiography-guided management did not result in a lower incidence of subsequent myocardial infarction or death from a cardiac cause than standard care. (Funded by the British Heart Foundation; TARGET-CTCA ClinicalTrials.gov number, NCT03952351.).
参考来源
- Lee KK, Wereski R, Lowe D, et al. Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain. N Engl J Med. 2026. PMID: 42670980. doi:10.1056/NEJMoa2608903
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。